It is known that PIK3CA gene mutations, mainly at the level of hotspots in exons 9 (codons 542 and 545) and 20 (codon 1047), confer constitutive oncogenic pathway activation in different types of cancer, including breast cancer [13], for which it is considered a therapeutic target as well [14]. The gene discussed is PIK3CA; the disease is breast carcinoma.